A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study)
JOURNAL OF NEUROENDOCRINOLOGY（2022）
关键词
neuroendocrine carcinoma, folfiri, captem, second line, phase 2, nec, temozolomide, capecitabine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要